Dr. Anne Lesage is Chief Early Development Officer at Pharvaris. Dr. Lesage is a co-founder of Pharvaris and has led the translational science, preclinical and non-clinical development since its inception. Dr. Lesage has over 30 years’ experience in drug discovery, preclinical, and early development.
From 1992 until 2010, Dr. Lesage held different leadership positions with increasing responsibility in the neuroscience drug discovery unit at Johnson & Johnson. By 2005, Dr. Lesage served as the biology head of psychiatry.
Dr. Lesage is an inventor on 10 patents and an author of 46 publications. Dr. Lesage founded GrayMatters Consulting in 2010 and advises early and late-stage biotech companies, venture capital organizations, and government agencies and initiatives. In 2013, Dr. Lesage co-founded Kosa Pharma.
Dr. Lesage is trained as a biochemist and holds a Ph.D. in molecular biology. Dr. Lesage studied biochemistry at the University of Ghent, received her Ph.D. in the group of Professor Walter Fiers, and was a post-doctoral fellow in the Child Psychiatry department of Stanford University Medical School and in the CNRS Laboratory of Viral Oncology of Hospital Paul Brousse in Paris.
What is Anne Lesage's net worth?
The estimated net worth of Anne Lesage is at least $1.78 million as of April 30th, 2026. Dr. Lesage owns 56,450 shares of Pharvaris stock worth more than $1,778,740 as of June 11th. This net worth evaluation does not reflect any other assets that Dr. Lesage may own. Learn More about Anne Lesage's net worth.
How do I contact Anne Lesage?
Has Anne Lesage been buying or selling shares of Pharvaris?
Over the course of the past ninety days, Anne Lesage has sold $1,787,658.00 in shares of Pharvaris stock. Most recently, Anne Lesage sold 21,700 shares of the business's stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.26, for a transaction totalling $656,642.00. Following the completion of the sale, the insider now directly owns 56,450 shares of the company's stock, valued at $1,708,177. Learn More on Anne Lesage's trading history.
Who are Pharvaris' active insiders?
Pharvaris' insider roster includes Elisabeth Bjork (Director), Robert Glassman (Director), Anne Lesage (Chief Early Development Officer), Anne Lesage (Insider), Peng Lu (Chief Medical Officer), Berndt Modig (Chief Executive Officer, Director (CH)), Viviane Monges (Director), David Nassif (CFO), Anna Nijdam (Insider), and Wim Souverijns (Insider). Learn More on Pharvaris' active insiders.
Are insiders buying or selling shares of Pharvaris?
In the last twelve months, insiders at the sold shares 25 times. They sold a total of 212,618 shares worth more than $6,350,563.86. The most recent insider tranaction occured on June, 4th when insider Anna Nijdam sold 2,670 shares worth more than $82,422.90. Insiders at Pharvaris own 11.8% of the company.
Learn More about insider trades at Pharvaris. Information on this page was last updated on 6/4/2026.
